Clinical Trials Logo
  1. Home
  2. Bladder Carcinoma
  3. NCT03824691

hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study" — ARCADIA  

Bladder Carcinoma Clinical Trial

Official title:
Cabozantinib Plus Durvalumab in Patients With Advanced and Chemotherapy-treated Bladder Carcinoma, of Urothelial and Non-urothelial Histology: an Open-label, Single-centre, Phase 2, Single-arm Proof-of-concept Trial: ARCADIA Study

Clinical Trial Summary

Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-of-concept trial: ARCADIA study

Clinical Trial Description

an open-label, single-centre, phase 2, ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03824691
Study type Interventional
Source Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Contact Patrizia Giannatempo, MD
Phone +390223902402
Email patrizia.giannatempo@istitutotumori.mi.it
Status Recruiting
Phase Phase 2
Start date September 25, 2019
Completion date February 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Active, not recruiting NCT05399004 - Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer
Recruiting NCT04502095 - Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy Phase 4
Completed NCT03125226 - TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer N/A
Withdrawn NCT05564416 - Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial Phase 2
Terminated NCT02169284 - Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery Phase 2
Recruiting NCT05519878 - Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers N/A
Active, not recruiting NCT02439060 - PUBMIC (Prophylactic Use of Biologic Mesh in Ileal Conduit) N/A
Recruiting NCT04410302 - Patient-Derived Xenografts to Reduce Cancer Health Disparities
Withdrawn NCT04054752 - Vaccine Response With NT-I7 Phase 1
Terminated NCT03549650 - Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms Phase 2
Completed NCT00469066 - Cone Beam CT Scanning in Lung and Bladder Cancer. N/A
Active, not recruiting NCT03757949 - Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery Phase 3
Completed NCT03064308 - The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery N/A
Active, not recruiting NCT02432963 - Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Phase 1
Active, not recruiting NCT02408406 - PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers N/A
Recruiting NCT06109857 - Bladder Bank (a Prospective Banking Study)
Terminated NCT02145390 - Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy N/A
Terminated NCT01245660 - A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy Phase 0
Withdrawn NCT02438852 - Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer Phase 3